Clinical Trials and Research

Introduction. Heart failure (HF) is a leading cause of hospitalization in Internal Medicine and HF with preserved ejection fraction (HFpEF) accounts for…

TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2…

AbstractBackgroundIn the phase III Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (HELIOS-B), vutrisiran significantly…

AbstractThe therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-…

Injectable therapy shows consistent benefits across high-risk ATTR-CM groupsNew analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial…

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  ––   CR rate now 95% (19 of 20…

Multiparametric scores are effective for validating the AL score and increased wall thickness (IWT) scores in AL amyloidosis, according to a study being presented…

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics,…

This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released…

Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that may occur in hereditary or wild-type forms. Although more than 150…